摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-4-氟-苯丙酮 | 202865-82-5

中文名称
3-溴-4-氟-苯丙酮
中文别名
3′-溴-4′-氟苯乙酮
英文名称
3-bromo-4-fluoropropiophenone
英文别名
3'-Bromo-4'-fluoropropiophenone;1-(3-bromo-4-fluorophenyl)propan-1-one
3-溴-4-氟-苯丙酮化学式
CAS
202865-82-5
化学式
C9H8BrFO
mdl
——
分子量
231.064
InChiKey
IZSXDWBFACKNSW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    60-64 °C
  • 密度:
    1.4965 (rough estimate)
  • 稳定性/保质期:
    避氧化物

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2914700090
  • 安全说明:
    S26,S37/39
  • 危险类别码:
    R36/37/38

SDS

SDS:0e4e52561778958cffcad0671274b88f
查看

反应信息

点击查看最新优质反应信息

文献信息

  • 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    申请人:Neustadt R. Bernard
    公开号:US20070066620A1
    公开(公告)日:2007-03-22
    Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R 1 -isoxazolyl, R 1 -oxadiazolyl, R 1 -dihydrofuranyl, R 1 -pyrazolyl, R 1 -imidazolyl, R 1 -pyrazinyl or R 1 -pyrimidinyl; R 1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.
    具有结构式I或其药用可接受盐的化合物,其中R是R1-异噁唑基、R1-噁唑啉基、R1-二氢呋喃基、R1-吡唑基、R1-咪唑基、R1-吡啶基或R1-嘧啶基;R1是从H、烷基、烷氧基和卤代中选择的1、2或3个取代基;Z是可选择取代的芳基或可选择取代的杂芳基;公开了这些化合物及其在治疗中枢神经系统疾病,特别是帕金森病和额外锥体综合征中的用途,包括它们的药物组合物和与其他药剂的组合。
  • Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
    申请人:Neustadt R. Bernard
    公开号:US20050239795A1
    公开(公告)日:2005-10-27
    Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    具有结构式I或其药学上可接受的盐的化合物,其中R是可选择地取代的苯基、呋喃基、噻吩基、吡啶基、吡啶N-氧化物基、噁唑基或吡咯基,或环烯基R1、R2、R3、R4和R5为H、烷基或烷氧基烷基;Z是可选择地取代的芳基或杂芳基。还公开了公式I化合物在治疗中枢神经系统疾病,特别是帕金森病中的用途,单独或与其他治疗帕金森病的药剂联合使用,以及包含它们的药物组合物。
  • N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
    申请人:GRIFFIOEN Gerard
    公开号:US20100197703A1
    公开(公告)日:2010-08-05
    This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.
    该发明提供了噻唑基哌嗪衍生物,以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物,以及其药学上可接受的盐,这些是用于治疗α-突触核蛋白病的有效活性成分,如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法,以及包括这些衍生物和药学上可接受的辅料的药物组合物。
  • Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators
    申请人:Katamreddy Subba Reddy
    公开号:US20080255078A1
    公开(公告)日:2008-10-16
    Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.
    提供了公式(I)的三苯乙烯化合物。这些化合物特别适用于选择性雌激素受体调节。
  • 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS
    申请人:CONVERGENCE PHARMACEUTICALS LIMITED
    公开号:US20150225400A1
    公开(公告)日:2015-08-13
    The invention relates to spiro derivatives of formula (I), to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation.
    本发明涉及公式(I)的螺内酯衍生物,涉及使用该衍生物治疗通过调节电压门控钠通道介导的疾病和病症,涉及含有该衍生物的组合物和其制备过程。
查看更多